Navigation Links
Phase 3 Study of VX-770 Shows Marked Improvement in Lung Function Among People with Cystic Fibrosis with G551D Mutation
Date:2/23/2011

BETHESDA, Md., Feb. 23, 2011 /PRNewswire-USNewswire/ -- The Cystic Fibrosis Foundation and Vertex Pharmaceuticals announced today that VX-770, an oral medicine in development that targets the defective protein that causes cystic fibrosis, showed promising results in a Phase 3 clinical trial.

The trial was designed to evaluate patients age 12 and up who carry at least one copy of a CF mutation called G551D. The study included 161 patients who received at least one dose of VX-770 or placebo.

Patients who took the drug, compared to those on placebo, showed a marked improvement in lung function at 24 weeks, which was sustained for the duration of the 48-week trial.

Patients also showed improvement across all key secondary endpoints in the study, including reduced likelihood of experiencing a pulmonary exacerbation, decreased respiratory symptoms and improved weight gain. Each of these areas is critically important to the health of people with CF.

In addition, average sweat chloride levels of patients on VX-770 dropped toward normal levels, while those on placebo did not change—indicating the drug is impacting the underlying defect in CF. Excessive sweat chloride (salt) is a key clinical indicator of CF.

VX-770 is being developed by Vertex, and was discovered in collaboration with the CF Foundation, which provided substantial support to Vertex throughout the development process, including an approximately $75 million investment.

About four percent of people with CF carry the G551D mutation. More studies are needed to determine whether other CF mutations may benefit from VX-770.

"These results are highly encouraging. They provide scientific evidence that support our long-standing belief that targeting the underlying defect of CF may have a profound effect on the disease," said Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation. "We have much more to do to end the suffering caused by thi
'/>"/>

SOURCE Cystic Fibrosis Foundation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , 7 de julio de 2015 /PRNewswire/ ... de propiedad privada centrada en el desarrollo de ... neurovascular, ha anunciado hoy que R. Michael ... directiva. Kleine cuenta con más ... de los dispositivos médicos y la sanidad. Ha ...
(Date:7/7/2015)... , July 7, 2015 According ... by Method (Manual, Automated), Product (Consumables, Instrument), Application (Aerobic, Anaerobic, ... Academic Research Institute) - Forecast to 2019", published by MarketsandMarkets, ... $3,893.5 Million by 2019 from $2,750.2 Million in 2014 at ... 1 78 ma rket ...
(Date:7/7/2015)... Md. , July 7, 2015 ... (CRO) focusing in Oncology, Vaccines, and General Medicine ... the final locked database to Heron Therapeutics, Inc. ... 3 receptor antagonist product candidate SUSTOL® (granisetron ... regimen with the IV NK 1 receptor ...
Breaking Medicine Technology:Sequent Medical nombra a Mike Kleine a su junta directiva 2Sequent Medical nombra a Mike Kleine a su junta directiva 3Blood Culture Tests Market Worth $3,893.5 Million by 2019 2Blood Culture Tests Market Worth $3,893.5 Million by 2019 3Blood Culture Tests Market Worth $3,893.5 Million by 2019 4Accelovance Completes Trial Enrollment and Delivery of Clinical Data for Heron Therapeutics' Phase 3 Trial 2
... Supreme Court decision in Pliva v. Mensing is ... legal immunity when they ignore harmful side-effects of the drugs ... for generic manufacturers to ensure their drug is safe and ... This decision also means that brand-name manufacturers will be held ...
... Ill., June 23, 2011 Akorn, Inc. (NASDAQ: ... Tuesday, August 2, 2011, to discuss second quarter 2011 ... the same day before the market opens. Subject: , ... 2, 2011, at 10:00 a.m. Eastern TimeDomestic Callers: , ...
Cached Medicine Technology:Generic Drug Decision Disastrous to Patient Safety 2
(Date:7/7/2015)... ... 2015 , ... SC&H Group, a leading audit, tax, and consulting firm, recently ... community through company-wide volunteering efforts. , On an annual basis, in coordination with ... in need throughout Baltimore and Washington D.C. , This year, SC&H Group’s ...
(Date:7/7/2015)... , ... July 07, 2015 , ... ... further enhance the experience for its patient community using its IDF ePHR, an ... patients with primary immunodeficiency diseases (PI) to easily track their health information, including ...
(Date:7/7/2015)... ... , ... FSAstore.com today announced the launch of its sister site ... simple to use, spend and manage HSA funds with innovative tools including an ... to a report by Devenir , approximately 13.8 million Americans have an HSA, ...
(Date:7/7/2015)... ... 2015 , ... America is blessed with people who continually go above and ... offers a special way to say “thanks.” Give them the recognition they deserve by ... their place on the “Wall of Heroes.” , “We hear the stories about ...
(Date:7/7/2015)... ... July 07, 2015 , ... RadSite™, a leading ... by the Centers for Medicare and Medicaid Services (CMS), announces that it has ... mobile devices. , The most effective websites are those that provide timely information, ...
Breaking Medicine News(10 mins):Health News:SC&H Group Celebrates 9th Annual Day of Service 2Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 2Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 3Health News:Introducing HSAstore.com: A New E-commerce Site for Health Savings Account Eligible Products and Services 2Health News:Introducing HSAstore.com: A New E-commerce Site for Health Savings Account Eligible Products and Services 3Health News:California Casualty Wants to Know: "Who Is Your Hero?" 2Health News:RadSite Releases Mobile-friendly Website for Enhanced User Experience 2Health News:RadSite Releases Mobile-friendly Website for Enhanced User Experience 3
... Caremark Corporation (NYSE: CVS ) today announced ... dividend of $0.07625 per share on the Common Stock ... of record on April 22, 2009.(Logo: http://www.newscom.com/cgi-bin/prnh/20090226/NE75914LOGO ... prescriptions in the nation. The Company fills or manages ...
... want to lose fat instead of muscle. Not if you want ... develop diabetes and heart disease. Not if you want to avoid ... if you want to keep the weight off long-term. , "Our ... these goals if you follow a diet that is moderately high ...
... Calif., March 4, 2009 Chronic kidney disease increases the ... most common type of heart arrhythmia, according to a new ... of Circulation . , It has long been known ... disease. This study is the first to look at whether ...
... Provider, Seeing More Than 250,000 Patients Per Year, ... March 4 Greenway Medical Technologies, a leading ... management and interoperability functionality, today announced that it ... Prime Suite (R) , into ...
... and Exclusive Tickets to Go to AAPD WASHINGTON, ... exclusive tickets will be auctioned off beginning March ... with Disabilities (AAPD), the country,s largest cross-disability membership ... being held in conjunction with the Recording Industry ...
... Expects Accelerated Revenue Growth From World,s Largest EconomyMISSISSAUGA, ON, ... global leader in developing drug free, non-invasive low level ... relief, today announced that the company has received CE ... MedX laser and light products in all 25 European ...
Cached Medicine News:Health News:Is one diet as good as another? U of I study says no and tells you why 2Health News:Is one diet as good as another? U of I study says no and tells you why 3Health News:Kidney disease increases the risk of stroke in patients 2Health News:Greenway Medical Technologies Partners With Pediatric Associates, the Nation's Largest Ambulatory Provider of General Pediatric Care 2Health News:Greenway Medical Technologies Partners With Pediatric Associates, the Nation's Largest Ambulatory Provider of General Pediatric Care 3Health News:Celebrity Memorabilia Auction to Benefit AAPD 2Health News:MedX Health Receives CE Mark for Laser & Light Products 2Health News:MedX Health Receives CE Mark for Laser & Light Products 3
... immunofluorescent antibody (IFA) test ... semi-quantitation of human serum ... viral capsid antigen (VCA). ... 12-well slides, FITC IgG ...
CMF OL1000 Bone Growth Stimulators are portable, battery-powered medical devices indicated for use in the noninvasive treatment of an established nonunion fracture acquired secondary to trauma, exclu...
... bone growth stimulator for the treatment of ... bone growth stimulator is a useful adjunct ... is already planned or when patient compliance ... is totally surgically implanted, patients are assured ...
... Stryker is proud to ... resectoscopes on the market at ... ergonomic design incorporates a superior ... and intuitive locking mechanisms. The ...
Medicine Products: